Based on the report from the Clinical Cancer Registry Regensburg in Bavaria, Germany, among 4480 patients with non metastatic breast cancers, these immunohistochemical results divided tumors in Luminal A (found in 48.4% patients), Luminal B (24.8% patients), HER2-like (17.8% patients) and Basal-like (found in 9.0% patients) [2]. This evidence concerns the gene ERBB2 and breast carcinoma.